C12N 2760/00061
Methods of inactivation or attenuation
C12N2760/00061 (Methods of inactivation or attenuation) appears on 14 US grants and 20 published applications in this corpus.
Search patents in C12N- Granted patents
- 14
- Published applications
- 20
- Assignees
- 17
- Inventors
- 28
- Latest grant
- 6 Aug 2024
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2009 | 0 | 1 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 1 | 2 |
| 2013 | 0 | 0 |
| 2014 | 1 | 1 |
| 2015 | 2 | 2 |
| 2016 | 0 | 2 |
| 2017 | 0 | 0 |
| 2018 | 3 | 4 |
| 2019 | 1 | 2 |
| 2020 | 1 | 0 |
| 2021 | 0 | 2 |
| 2022 | 2 | 2 |
| 2023 | 1 | 0 |
| 2024 | 2 | 2 |
By publication year.
Subgroups
Granted patents
Recent patents
- Vaccine candidates for human respiratory syncytial virus (RSV) having attenuated phenotypes6 Aug 2024US 12,054,519 B2Codagenix Inc.
- Attenuation of human respiratory syncytial virus by genome scale codon-pair deoptimization6 Aug 2024US 12,054,749 B2The Research Foundation for The State University of New York
- Unit operation and use thereof17 Oct 2023US 11,786,615 B2Bayer Aktiengesellschaft
- Vaccine candidates for human respiratory syncytial virus (RSV) having attenuated phenotypes19 Jul 2022US 11,390,651 B2Codagenix Inc.
- Attenuation of human respiratory syncytial virus by genome scale codon-pair deoptimization28 Jun 2022US 11,371,024 B2The Research Foundation for The State University of New York
- Vaccine candidates for human respiratory syncytial virus (rsv) having attenuated phenotypes19 Dec 2024US 2024/0417431 A1Codagenix Inc.
- Attenuation of human respiratory syncytial virus by genome scale codon-pair deoptimization19 Dec 2024US 2024/0417699 A1The Research Foundation for The State University of New York
- Vaccine candidates for human respiratory syncytial virus (rsv) having attenuated phenotypes27 Oct 2022US 2022/0340619 A1Codagenix Inc.
- Attenuation of human respiratory syncytial virus by genome scale codon-pair deoptimization13 Oct 2022US 2022/0325252 A1The Research Foundation for The State University of New York
- Vaccine candidates for human respiratory syncytial virus (rsv) having attenuated phenotypes24 Jun 2021US 2021/0188920 A1Codagenix Inc.
Most cited
By later US patents
- Human binding molecules capable of neutralizing influenza virus H5N1 and uses thereof60US 8,691,223 B2Crucell Holland B. V. · 2014
- Human bind molecules capable of neutralizing influenza virus h5n1 and uses thereof46US 8,192,927 B2Crucell Holland B. V. · 2012
- Attenuation of human respiratory syncytial virus by genome scale codon-pair deoptimization7US 9,957,486 B2The Research Foundation for The State University of New York · 2018
- Vaccine candidates for human respiratory syncytial virus (RSV) having attenuated phenotypes4US 10,808,012 B2Codagenix Inc. · 2020
- Attenuation of human respiratory syncytial virus by genome scale codon-pair deoptimization2US 11,371,024 B2The Research Foundation for The State University of New York · 2022